AIM
MRNA icon

Allstate Investment Management’s Moderna MRNA Stock Holding History

Allstate Investment Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		$2.55M Buy
+14,190
New +$2.32M 0.08% 170

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
Coatue Management
Coatue Management New York $48.6B AUM 94.27% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Allstate Investment Management's MRNA Position: Q4 2022 in Review

Allstate Investment Management opened a new position in Moderna (MRNA) in Q4 2022: 14,190 shares worth $2.55M. The stake represents 0.08% of the portfolio and ranks #170 among its holdings.

1,071 funds tracked by Wall St. Rank hold MRNA as of Q4 2022.

  • Allstate Investment Management held 14,190 shares of Moderna worth $2.55M as of Q4 2022.
  • Moderna was a new Allstate Investment Management position in Q4 2022.
  • Moderna made up 0.08% of Allstate Investment Management's portfolio in Q4 2022, its #170 holding.
  • 1,071 funds tracked by Wall St. Rank held Moderna as of Q4 2022.

Based on Allstate Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.